Pharmaceutical Regulatory Environment

1. Overview of Medicines Regulatory Systems in the Gulf Region.- 2. The Regulatory Review Process in the Gulf Region.- 3. Regulatory Review Times in the Gulf Region.- 4. Quality Measures in the Gulf Regulatory Practices.- 5. The Current Status of the Common Technical Document.- 6. The Current Status of Drug Safety and Pharmacovigilance.- 7. The Centralized Regulatory Review in the Gulf Region.- 8. The Gulf States Assessment and Experience With the Centralised Procedure.- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure.- 10. Proposal For an Improved Centralized Regulatory System.- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions.- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.

Reem Al-Essa BPharm MSc PhD was the Drug Registration and Release Superintendent for six years of her 12 years experience with Ministry of Health, Kuwait. During this period she completed her MBA with distinction. She later undertook the EU2P MSc in Pharmacovigilance and Pharmacoepidemiology. Dr Al-Essa has published six journal articles and abstracts related to pharmaceutical regulation in the Gulf region. Mohammed Hamdan Al-Rubaie BPharm MSc PhD is the Director of Drug Control, Directorate General of Pharmaceutical affairs and Drug Control, Oman Ministry of Health.He is a member of the GCC Central Registration Committee, and actively involved in many other GCC committees and working groups for the drafting of the GCC pharmaceutical regulations and policies. Dr Al-Rubaie was instrumental in forming the Pharmaceutical society in Oman and chaired it from 2010-2011.

Stuart Walker BSc, PhD, MFPM FRSC FIBiol, FRCPath, is the Founder of the Centre for Medicines Research International, the Centre for Innovation in Regulatory Science and Professor of Pharmaceutical Medicine, University of Wales, Cardiff. During his research career in academia & industry, he has supervised many PhD programmes in clinical development, regulatory policies, the benefit/risk assessment of medicines and health technology assessment, co-authored 280 research papers and edited 25 books. He is frequently involved in the organisation of international meetings on key issues that concern the regulatory review of medicines and has lectured extensively throughout Europe, the USA, the Asia-Pacific Region, Latin America and the Middle East.